Compare CVRX & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | STXS |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.1M | 182.3M |
| IPO Year | 2021 | 2004 |
| Metric | CVRX | STXS |
|---|---|---|
| Price | $7.72 | $2.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $11.20 | $4.00 |
| AVG Volume (30 Days) | 219.0K | ★ 333.8K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,651,000.00 | $29,346,617.00 |
| Revenue This Year | $16.65 | $28.22 |
| Revenue Next Year | $18.41 | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $4.37 | $1.69 |
| 52 Week High | $11.30 | $3.59 |
| Indicator | CVRX | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 45.40 | 57.94 |
| Support Level | $6.51 | $1.97 |
| Resistance Level | $8.70 | $2.52 |
| Average True Range (ATR) | 0.76 | 0.09 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 35.05 | 98.21 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.